Short‐duration treatment with the novel non‐nucleoside inhibitor CDI‐31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open‐label study

Combination regimens of direct‐acting antiviral agents (DAAs) for chronic genotype 1 hepatitis C virus (HCV) infection given for 8 or 12 weeks have high cure rates. Shortened treatment durations that maintain high cure rates may lessen treatment barriers related to affordability and drug adherence....

Descripción completa

Detalles Bibliográficos
Autores principales: Chua, Joel V., Ntem‐Mensah, Afua, Abutaleb, Ameer, Husson, Jennifer, Mutumbi, Lydiah, Lam, Ka Wing, Ghosh, Alip, Romani, Sara, Poonia, Bhawna, Lee, Sam, Luz Pascual, M., Frumkin, Lyn R., Kottilil, Shyamsundaran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246884/
https://www.ncbi.nlm.nih.gov/pubmed/33150966
http://dx.doi.org/10.1002/jmv.26652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246884/
https://www.ncbi.nlm.nih.gov/pubmed/33150966
http://dx.doi.org/10.1002/jmv.26652

Ejemplares similares